- Companies with current Notes available
- Avacta Group PLC - AVCT - AffiDX Receives CE Mark for Consumer Self-Testing
- Avacta Group PLC - AVCT - Final Results
- Avacta Group PLC - AVCT - Rapid Antigen Test Detects SARS-CoV-2 Variants
- Avacta Group PLC - AVCT - Alastair Smith provides overview of pre|CISION™ prodrug technology and update on AVA6000 clinical trial
- Avacta Group PLC - AVCT - How a Lateral Flow Rapid Test Works
Our mission is to shape the future of medicine by developing safe and efficacious drugs, and powerful research and diagnostic tools, based on our proprietary Affimer® and pre|CISIONTM platforms.
Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company’s therapeutics development activities are based in Cambridge, UK.
The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.
Yorkshire & North East